Shares in Redx Pharma Plc (LON:REDX) jumped more than 7% on Monday morning after it confirmed it will make a clinical trial application (CTA) and investigational new drug (IND) application for its RXC005 leukaemia treatment later this year.
The confirmation comes after the drug researcher and developer presented further “potent efficacy data” at the prestigious 17th International Workshop of Chronic Lymphocytic Leukaemia (iwCLL) in New York over the weekend.
RXC005 – a Bruton’s tyrosine kinase inhibitor or BTK for short – is being designed for use in people with chronic lymphocytic leukaemia.
Importantly, it is also targeting those who have built up a resistance to the current best-in-class treatment, Imbruvica (often referred to as Ibrutinib).
The drug is being developed as a second-generation of compound which has fewer side-effects than the market leader.
RXC005 demonstrates “significant efficacy”
The data presented showed that the drug successfully inhibits wild-type BTK, mutant BTK as well as primary CLL cells.
RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members, Redx added.
“The data presented is further validation of RXC005's potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment,” said chief scientific officer Richard Amer.
“With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic.”
Chief executive Neil Murray added: “We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries.”
Shares were up 7.5% to 32.5p shortly before midday.
--Updates for share price--